Preferential activation of type I interferon-mediated antitumor inflammatory signaling by CuS/MnO 2 /diAMP nanoparticles enhances anti-PD-1 therapy for sporadic colorectal cancer.

Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Colorectal Neoplasms*/drug therapy ; Colorectal Neoplasms*/pathology ; Manganese Compounds*/chemistry ; Manganese Compounds*/pharmacology ; Oxides*/chemistry ; Oxides*/pharmacology ; Interferon Type I*/metabolism ; Tumor Microenvironment*/drug effects ; Signal Transduction*/drug effects ; Nanoparticles*/chemistry; Animals ; Mice ; Cell Line, Tumor ; Humans ; Copper/chemistry ; Copper/pharmacology ; Mice, Inbred C57BL ; Mice, Inbred BALB C ; Programmed Cell Death 1 Receptor/metabolism ; Inflammation/drug therapy ; Immune Checkpoint Inhibitors/pharmacology ; Female ; Apoptosis/drug effects ; Membrane Proteins/metabolism

Competing Interests: DeclarationsEthics approval and consent to participate All animal procedures were performed following protocols approved by the Institutional Animal Care and Treatment Committee of Sichuan University (Chengdu, P. R. China) and West China Hospital, Sichuan University (Approved number: 2021755A) as well as Chengdu Medical College (Approved number: 2022037). Consent for publication Consents for publication were obtained from all the authors of this study. Competing interests The authors declare no competing interests.
Converting the "cold" tumor microenvironment (TME) to a "hot" milieu has become the prevailing approach for enhancing the response of immune-excluded/immunosuppressed colorectal cancer (CRC) patients to immune checkpoint blockade (ICB) therapy. During this process, inflammation accompanied by different kinds of chemokines/cytokines inevitably occurs. However, some activated inflammatory signals exhibit protumor potency. Therefore, strategies that preferentially activate antitumor inflammatory signaling rather than tumor-promoting signaling need to be developed. Herein, we constructed a STING agonist-loaded CuS/MnO 2 bimetallic nanosystem, termed diAMP-BCM. BCM with an optimized Cu/Mn ratio efficiently promoted the activation of proinflammatory signaling, and in combination with the STING agonist diAMP, diAMP-BCM controllably activated tumoricidal inflammatory signaling in APCs. DiAMP-BCM can efficiently generate ROS and promote the activation of STING, which induces the apoptosis of cancer cells and promotes the recruitment of monocytes while facilitating the polarization of macrophages and maturation of DCs. MC38 and CT26 CRC models were established to evaluate the in vivo antitumor effects of diAMP-BCM. Combined with ICB therapy, diAMP-BCM enables the rebuilding of tumor milieus with efficient tumor growth inhibition and alleviation of T-cell exhaustion, particularly in distal tumors, in sporadic colorectal cancer therapy. This study established a nanoplatform to promote the preferential activation of antitumor inflammatory signaling, rebuild the T-cell repertoire and alleviate T-cell exhaustion to enhance cancer ICB immunotherapy.
(© 2024. The Author(s).)

N Engl J Med. 2020 Dec 3;383(23):2207-2218. (PMID: 33264544)
Sci Transl Med. 2022 Nov 9;14(670):eabo3605. (PMID: 36350989)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
Immunity. 2016 Mar 15;44(3):698-711. (PMID: 26982367)
Nat Immunol. 2022 Nov;23(11):1614-1627. (PMID: 36289450)
Differentiation. 2003 Mar;71(2):114-25. (PMID: 12641565)
J Control Release. 2024 Mar;367:300-315. (PMID: 38281670)
Signal Transduct Target Ther. 2024 Mar 4;9(1):53. (PMID: 38433280)
Nat Immunol. 2020 Aug;21(8):868-879. (PMID: 32690950)
Immunity. 2018 Apr 17;48(4):675-687.e7. (PMID: 29653696)
Trends Cancer. 2024 May;10(5):444-456. (PMID: 38360438)
Cell Metab. 2023 Jan 3;35(1):134-149.e6. (PMID: 36528023)
Sci Transl Med. 2016 Feb 24;8(327):327ra26. (PMID: 26912905)
ACS Appl Mater Interfaces. 2017 Apr 26;9(16):13875-13886. (PMID: 28374581)
Sci Bull (Beijing). 2023 Mar 30;68(6):622-636. (PMID: 36914548)
Adv Mater. 2024 Jun;36(23):e2311291. (PMID: 38408154)
Trends Immunol. 2014 Nov;35(11):571-80. (PMID: 25443495)
JAMA Oncol. 2023 Mar 1;9(3):404-413. (PMID: 36701146)
Nat Rev Clin Oncol. 2022 Apr;19(4):237-253. (PMID: 34997230)
Nat Immunol. 2023 Sep;24(9):1527-1539. (PMID: 37537361)
Nature. 2019 Oct;574(7776):45-56. (PMID: 31578484)
Adv Drug Deliv Rev. 2019 Mar 15;143:37-67. (PMID: 31276708)
Nat Commun. 2020 Jun 3;11(1):2788. (PMID: 32493916)
Nat Rev Cancer. 2021 May;21(5):281-297. (PMID: 33758415)
Nat Commun. 2022 Nov 28;13(1):7316. (PMID: 36443332)
ACS Appl Mater Interfaces. 2024 Oct 9;16(40):53393-53404. (PMID: 39324588)
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375. (PMID: 30886395)
Trends Cell Biol. 2024 Oct;34(10):865-881. (PMID: 38423853)
Nat Immunol. 2011 Jul 19;12(8):715-23. (PMID: 21772280)
Adv Healthc Mater. 2024 Jan;13(1):e2302023. (PMID: 37742127)
Drug Deliv. 2019 Dec;26(1):1254-1264. (PMID: 31760842)
Cancer Cell. 2023 Jun 12;41(6):1152-1169.e7. (PMID: 37172580)
Nat Nanotechnol. 2024 Jun;19(6):856-866. (PMID: 38480836)
Nature. 2020 Jan;577(7791):561-565. (PMID: 31942071)
Nat Rev Drug Discov. 2019 Mar;18(3):197-218. (PMID: 30610226)
Cancer Res. 2004 Oct 1;64(19):6965-72. (PMID: 15466188)
Nature. 2023 Aug;620(7976):1080-1088. (PMID: 37612508)
Nat Rev Immunol. 2021 Oct;21(10):653-667. (PMID: 33911231)
Theranostics. 2020 Jan 1;10(4):1500-1513. (PMID: 32042318)
CA Cancer J Clin. 2023 May-Jun;73(3):233-254. (PMID: 36856579)
Nano Lett. 2024 Jul 10;24(27):8217-8231. (PMID: 38848540)
Nat Cancer. 2021 Aug;2(8):794-802. (PMID: 35118423)
Nat Nanotechnol. 2021 Nov;16(11):1260-1270. (PMID: 34594005)
Angew Chem Int Ed Engl. 2022 Dec 12;61(50):e202209245. (PMID: 36264713)
Angew Chem Int Ed Engl. 2018 Apr 23;57(18):4902-4906. (PMID: 29488312)
EBioMedicine. 2022 Jun;80:104047. (PMID: 35561451)
Science. 2016 Dec 2;354(6316):1160-1165. (PMID: 27789795)
Nat Rev Immunol. 2022 Apr;22(4):209-223. (PMID: 34253904)
Cancer Cell. 2022 Jun 13;40(6):624-638.e9. (PMID: 35623342)
Traffic. 2023 Dec;24(12):576-586. (PMID: 37658794)

32171376 National Natural Science Foundation of China; 32371455 National Natural Science Foundation of China; 31930067 National Natural Science Foundation of China; 2024YFFK0205 the Key Research and Development Program of Sichuan Province; 2020JDJQ0048 Science and Technology Program for Distinguished Young Scholar of Sichuan Province; 2024NSFSC0044 Natural Science Foundation of Sichuan Province of China

0 (Manganese Compounds)
0 (Oxides)
0 (Interferon Type I)
789U1901C5 (Copper)
0 (Programmed Cell Death 1 Receptor)
0 (Immune Checkpoint Inhibitors)
TF219GU161 (manganese dioxide)
0 (Membrane Proteins)

Date Created: 20241113 Date Completed: 20241113 Latest Revision: 20241116

20250114

PMC11555826

10.1186/s12951-024-02970-y

39533269